Ayami Okuzumi

Ayami Okuzumi

Auto-generated profile, based on publicly available information

Ayami Okuzumi

Department of Neurology, Juntendo University Faculty of Medicine, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2023 in Nature Medicine
Verified
Journal Article
Open access
PDF file
AOAyami Okuzumi
Ayami Okuzumi
THTaku Hatano
Taku Hatano
GMGen Matsumoto
Gen Matsumoto
SNShuko Nojiri
Shuko Nojiri
SUShinichi Ueno
Shinichi Ueno
NHNobutaka Hattori
Nobutaka Hattori
Abnormal α-synuclein aggregation is a key pathological feature of a group of neurodegenerative diseases known as synucleinopathies, which include Parkinson’s disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA). The pathogenic β-sheet seed conformation of α-synuclein is found in various tissues, suggesting potential as a biomarker, but few studies have been able to reliably detect these seeds in serum samples. In this study, we developed a modified assay system, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), which enables the detection of pathogenic α-synuclein seeds in the serum of individuals with synucleinopathies. In our internal first and second cohorts, IP/RT-QuIC showed high diagnostic performance for differentiating PD versus controls (area under the curve (AUC): 0.96 (95% confidence interval (CI) 0.95–0.99)/AUC: 0.93 (95% CI 0.84–1.00)) and MSA versus controls (AUC: 0.64 (95% CI 0.49–0.79)/AUC: 0.73 (95% CI 0.49–0.98)). IP/RT-QuIC also showed high diagnostic performance in differentiating individuals with PD (AUC: 0.86 (95% CI 0.74–0.99)) and MSA (AUC: 0.80 (95% CI 0.65–0.97)) from controls in a blinded external cohort. Notably, amplified seeds maintained disease-specific properties, allowing the differentiation of samples from individuals with PD versus MSA. In summary, here we present a novel platform that may allow the detection of individuals with synucleinopathies using serum samples.

4 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
SSShinji Saiki
Shinji Saiki
THTaku Hatano
Taku Hatano
MFMotoki Fujimaki
Motoki Fujimaki
KIKei-ichi Ishikawa
Kei-ichi Ishikawa
AMAkio Mori
Akio Mori
NHNobutaka Hattori
Nobutaka Hattori
Increasing evidence shows that metabolic abnormalities in body fluids are distinguishing features of the pathophysiology of Parkinson’s disease. However, a non-invasive approach has not been established in the earliest or pre-symptomatic phases. Here, we report comprehensive double-cohort analyses of the metabolome using capillary electrophoresis/liquid chromatography mass-spectrometry. The plasma analyses identified 18 Parkinson’s disease-specific metabolites and revealed decreased levels of seven long-chain acylcarnitines in two Parkinson’s disease cohorts (n = 109, 145) compared with controls (n = 32, 45), respectively. Furthermore, statistically significant decreases in five long-chain acylcarnitines were detected in Hoehn and Yahr stage I. Likewise, decreased levels of acylcarnitine(16:0), a decreased ratio of acylcarnitine(16:0) to fatty acid(16:0), and an increased index of carnitine palmitoyltransferase 1 were identified in Hoehn and Yahr stage I of both cohorts, suggesting of initial β-oxidation suppression. Receiver operating characteristic curves produced using 12–14 long-chain acylcarnitines provided a large area of under the curve, high specificity and moderate sensitivity for diagnosing Parkinson’s disease. Our data demonstrate that a primary decrement of mitochondrial β-oxidation and that 12–14 long-chain acylcarnitines decreases would be promising diagnostic biomarkers for Parkinson’s disease.

30 April 2024 in Journal of Movement Disorders
Verified
Journal Article
Open access
PDF file
THTaku Hatano
Taku Hatano
AOAyami Okuzumi
Ayami Okuzumi
GMGen Matsumoto
Gen Matsumoto
TTTaiji Tsunemi
Taiji Tsunemi
NHNobutaka Hattori
Nobutaka Hattori
Mutations in the SNCA gene, which encodes α-synuclein (α-syn), play a key role in the development of genetic Parkinson’s disease (PD). α-Syn is a major component of Lewy bodies in PD and glial cytoplasmic inclusions in multiple system atrophy (MSA). Rapid eye movement sleep behavior disorder patients often progress to PD, dementia with Lewy bodies, or MSA, which are collectively known as α-synucleinopathies. The loss of dopaminergic neurons with Lewy bodies precedes motor dysfunction in these diseases, but the mechanisms of neurodegeneration due to α-syn aggregation are poorly understood. Monitoring α-syn aggregation in vivo could serve as a diagnostic biomarker and help elucidate pathogenesis, necessitating a simple and accurate detection method. Seed amplification assays (SAAs), such as real-time quaking-induced conversion and protein misfolding cyclic amplification, are used to detect small amounts of abnormally structured α-syn protofibrils, which are central to aggregation. These methods are promising for the early diagnosis of α-synucleinopathy. Differences in α-syn filament structures between α-synucleinopathies, as observed through transmission electron microscopy and cryo-electron microscopy, suggest their role in the pathogenesis of neurodegeneration. SAAs may differentiate between subtypes of α-synucleinopathy and other diseases. Efforts are also being made to identify α-syn from blood using various methods. This review introduces body fluid α-syn biomarkers based on pathogenic α-syn seeds, which are expected to redefine α-synucleinopathy diagnosis and staging, improving clinical research accuracy and facilitating biomarker development.

1 September 2021 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
ASAnri Sakurai
Anri Sakurai
TTTaiji Tsunemi
Taiji Tsunemi
YIYuta Ishiguro
Yuta Ishiguro
AOAyami Okuzumi
Ayami Okuzumi
THTaku Hatano
Taku Hatano
NHNobutaka Hattori
Nobutaka Hattori

14 February 2020 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
PDF file
SUShinichi Ueno
Shinichi Ueno
THTaku Hatano
Taku Hatano
AOAyami Okuzumi
Ayami Okuzumi
SSShinji Saiki
Shinji Saiki
YOYutaka Oji
Yutaka Oji
NHNobutaka Hattori
Nobutaka Hattori
Objective: To investigate the oxidized albumin ratio, which is the redox ratio of human nonmercaptalbumin (HNA) to serum albumin (%HNA), as a biomarker in idiopathic Parkinson’s disease (iPD) and related neurodegenerative disorders.Methods: This prospective study enrolled 216 iPD patients, 15 patients with autosomal recessive familial PD due to parkin mutations (PARK2), 30 multiple system atrophy (MSA) patients, 32 progressive nuclear palsy (PSP) patients, and 143 healthy controls. HNA was analyzed using modified high‐performance liquid chromatography and was evaluated alongside other parameters.Results: iPD and PARK2 patients had a higher %HNA than controls (iPD vs. controls: odds ratio (OR) 1.325, P < 0.001; PARK2 vs. controls: OR 1.712, P < 0.001). Even iPD patients at an early Hoehn & Yahr stage (I and II) showed a higher %HNA than controls. iPD patients had a higher %HNA than MSA and PSP patients (iPD vs. MSA: OR 1.249, P < 0.001, iPD vs. PSP: OR 1.288, P < 0.05). When discriminating iPD patients from controls, %HNA corrected by age achieved an AUC of 0.750; when discriminating iPD patients from MSA and PSP patients, an AUC of 0.747 was achieved. Furthermore, uric acid, an antioxidant compound, was decreased in iPD patients, similar to the change in %HNA.Interpretation: %HNA was significantly increased in iPD and PARK2 patients compared with controls, regardless of disease course and severity. Oxidative stress might be increased from the early stages of iPD and PARK2 and play an important role in their pathomechanisms.

1 February 2017 in Neurobiology of Aging
Verified
Journal Article
Closed access
TMTakashi Matsushima
Takashi Matsushima
SCSilvio Conedera
Silvio Conedera
RTRyota Tanaka
Ryota Tanaka
YLYuanzhe Li
Yuanzhe Li
HYHiroyo Yoshino
Hiroyo Yoshino
NHNobutaka Hattori
Nobutaka Hattori